Ultragenyx Pharmaceutical Stock Forecast

Stock Price Forecast

According to 20 analysts polled by S&P Global, Ultragenyx Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $26.79. The average 1-year stock price forecast is 75.44% higher than the current stock price, while the lowest is $16 (+4.78%) and the highest is $39 (+155.40%).

Price Target: $26.79 (+75.44%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$16	$26.79	$25	$39
Change	+4.78%	+75.44%	+63.72%	+155.40%

Analyst Ratings

The average analyst rating for Ultragenyx Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	May '26	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26
Strong Buy	12	12	12	13	8	8
Buy	5	5	5	5	2	2
Hold	2	2	2	2	10	10
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	19	19	19	20	20	20

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Luca Issi RBC Capital	RBC Capital	Hold Maintains $19	Hold	Maintains	$19	+24.43%	Oct 9, 2026
Tazeen Ahmad Bank of America Securities	Bank of America Securities	Hold Maintains $20	Hold	Maintains	$20	+30.98%	Oct 9, 2026
Ram Selvaraju H.C. Wainwright	H.C. Wainwright	Buy Reiterates $25	Buy	Reiterates	$25	+63.72%	Oct 8, 2026
Gavin Clark-Gartner Evercore ISI	Evercore ISI	Hold Maintains $16 → $18	Hold	Maintains	$16 → $18	+17.88%	Sep 21, 2026
Maxwell Skor Morgan Stanley	Morgan Stanley	Hold Reiterates $18 → $20	Hold	Reiterates	$18 → $20	+30.98%	Sep 21, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

763.29M

from 673.00M

13.42%

from 673.00M

Revenue Next Year

1.00B

from 763.29M

31.52%

from 763.29M

EPS This Year

-3.87

from -5.83

EPS Next Year

0.68

from -3.87

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	351.41M	363.33M	434.00M	560.00M	673.00M	763.29M
Revenue Growth	29.66%	3.39%	19.45%	29.03%	20.18%	13.42%
Operating Income	-381.74M	-648.92M	-569.00M	-536.00M	-535.00M	-414.93M
Net Income	-454.03M	-707.42M	-607.00M	-569.00M	-575.00M	-424.30M
EPS	-	-	-	-	-5.83	-3.87
Free Cash Flow	-	-	-	-	-472.00M	346.00M
No. Analysts	-	-	-	-	-	18

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	903.1M
Avg	763.3M
Low	701.9M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	34.2%
Avg	13.4%
Low	4.3%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-1.18
Avg	-3.87
Low	-4.96

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-